Veru Inc.

Directions Website

Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and oncology

06/15/2026

Veru Announces Clinical Supply Agreement with Novo Nordisk for Phase 2b PLATEAU Study.

“We appreciate Novo Nordisk providing Wegovy® clinical supply for our Phase 2b PLATEAU study. The study will evaluate the use of enobosarm, an investigational therapy, in combination with a GLP‑1 receptor agonist in older patients with obesity to explore its potential impact on weight loss, body composition and physical function over 68 weeks,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru.

Novo Nordisk provides Wegovy® solely for use within the study under a clinical supply agreement. Please see our 8‑K filing for further details.

Veru was featured in The Athletic, a New York Times company, in an article examining GLP-1s, muscle loss, and the evolvi...
06/11/2026

Veru was featured in The Athletic, a New York Times company, in an article examining GLP-1s, muscle loss, and the evolving debate around performance enhancement in sports.

The article highlights a key issue in GLP-1 weight loss: muscle loss. Veru is working to address this clinical challenge through enobosarm as an adjunctive therapy with GLP-1 drugs to help preserve lean muscle.

Veru’s CEO, Dr. Mitchell Steiner, was quoted in the article discussing enobosarm.

GLP-1s are not prohibited; the way they work means they might never be. Anti-doping authorities are still monitoring how athletes use them.

Address

2916 North Miami Avenue
Miami, FL
33137

Website

Alerts

Be the first to know and let us send you an email when Veru Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category